The Precision Health Initiative is conducted by Genuity Science. Learn more about our recent restructure here.

Genuity Science, Formerly WuXi NextCode, Reinvents Itself With US, Europe Focus

CHICAGO – Last month, WuXi NextCode changed its name to Genuity Science and announced plans to restructure as a single entity while it divests its operations in China in the wake of a controversy that reached the US Senate.

The move ushered in the final stage of a three-year transformation of the firm, which started when executive leadership and eventually company headquarters moved from Shanghai to Boston. The company expects to shed the China operations by the end of the year, CEO Rob Brainin said.

The newly renamed Genuity Science — which is not related to business analytics and IT management firm Genuity — offers contract genomics and artificial intelligence-driven data sourcing and data analytics services to the biopharmaceutical industry to support drug discovery and development. Brainin said to expect several announcements in the next few weeks and months as the reorganized company gets a handle on its new operations and business model.

In addition to its Boston base, Genuity Science has offices in Reykjavik, Iceland, and Dublin, as well as CAP-accredited, CLIA-certified sequencing laboratories in Woburn, Massachusetts, and Dublin.

“We’ve continued to build out the capabilities of both of those labs to be able to serve our biopharma customer base,” Brainin said.

The company’s new name, which plays on the word “ingenuity,” is more in line with its mission and strategic direction.

“We think of ourselves as a genomic data and insights company and what we do is bring together a diverse set of capabilities to be able to integrate genomics into biopharma,” Brainin said.

“We’ve got data sourcing and the creation of large-scale genomic and phenotypic datasets, as well as next-generation sequencing capabilities, as well as some advanced analytical capabilities, including AI,” Brainin said. “We bring those together in a way to help biopharma across the discovery and development continuum.”

See the full article